158 related articles for article (PubMed ID: 21037534)
1. Anti-OX40 prevents effector T-cell accumulation and CD8+ T-cell mediated skin allograft rejection.
Kinnear G; Wood KJ; Marshall D; Jones ND
Transplantation; 2010 Dec; 90(12):1265-71. PubMed ID: 21037534
[TBL] [Abstract][Full Text] [Related]
2. A diametric role for OX40 in the response of effector/memory CD4+ T cells and regulatory T cells to alloantigen.
Kinnear G; Wood KJ; Fallah-Arani F; Jones ND
J Immunol; 2013 Aug; 191(3):1465-75. PubMed ID: 23817421
[TBL] [Abstract][Full Text] [Related]
3. Type 2 immune deviation has differential effects on alloreactive CD4+ and CD8+ T cells.
Matesic D; Valujskikh A; Pearlman E; Higgins AW; Gilliam AC; Heeger PS
J Immunol; 1998 Nov; 161(10):5236-44. PubMed ID: 9820495
[TBL] [Abstract][Full Text] [Related]
4. Anti-OX40 stimulation in vivo enhances CD8+ memory T cell survival and significantly increases recall responses.
Ruby CE; Redmond WL; Haley D; Weinberg AD
Eur J Immunol; 2007 Jan; 37(1):157-66. PubMed ID: 17183611
[TBL] [Abstract][Full Text] [Related]
5. OX40-OX40 ligand interaction in T-cell-mediated immunity and immunopathology.
Ishii N; Takahashi T; Soroosh P; Sugamura K
Adv Immunol; 2010; 105():63-98. PubMed ID: 20510730
[TBL] [Abstract][Full Text] [Related]
6. Critical, but conditional, role of OX40 in memory T cell-mediated rejection.
Vu MD; Clarkson MR; Yagita H; Turka LA; Sayegh MH; Li XC
J Immunol; 2006 Feb; 176(3):1394-401. PubMed ID: 16424166
[TBL] [Abstract][Full Text] [Related]
7. NK cells contribute to the skin graft rejection promoted by CD4+ T cells activated through the indirect allorecognition pathway.
Ito A; Shimura H; Nitahara A; Tomiyama K; Ito M; Kanekura T; Okumura K; Yagita H; Kawai K
Int Immunol; 2008 Oct; 20(10):1343-9. PubMed ID: 18697765
[TBL] [Abstract][Full Text] [Related]
8. Different costimulatory and growth factor requirements for CD4+ and CD8+ T cell-mediated rejection.
Vu MD; Amanullah F; Li Y; Demirci G; Sayegh MH; Li XC
J Immunol; 2004 Jul; 173(1):214-21. PubMed ID: 15210777
[TBL] [Abstract][Full Text] [Related]
9. Role of CD4+ and CD8+ T cells in murine skin and heart allograft rejection across different antigenic desparities.
Youssef AR; Otley C; Mathieson PW; Smith RM
Transpl Immunol; 2004 Dec; 13(4):297-304. PubMed ID: 15589743
[TBL] [Abstract][Full Text] [Related]
10. CD154 on the surface of CD4+CD25+ regulatory T cells contributes to skin transplant tolerance.
Jarvinen LZ; Blazar BR; Adeyi OA; Strom TB; Noelle RJ
Transplantation; 2003 Nov; 76(9):1375-9. PubMed ID: 14627918
[TBL] [Abstract][Full Text] [Related]
11. Blockade of 4-1BB (CD137)/4-1BB ligand interactions increases allograft survival.
Cho HR; Kwon B; Yagita H; La S; Lee EA; Kim JE; Akiba H; Kim J; Suh JH; Vinay DS; Ju SA; Kim BS; Mittler RS; Okumura K; Kwon BS
Transpl Int; 2004 Aug; 17(7):351-61. PubMed ID: 15349720
[TBL] [Abstract][Full Text] [Related]
12. Critical role of OX40 in CD28 and CD154-independent rejection.
Demirci G; Amanullah F; Kewalaramani R; Yagita H; Strom TB; Sayegh MH; Li XC
J Immunol; 2004 Feb; 172(3):1691-8. PubMed ID: 14734751
[TBL] [Abstract][Full Text] [Related]
13. Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients.
Blazar BR; Sharpe AH; Chen AI; Panoskaltsis-Mortari A; Lees C; Akiba H; Yagita H; Killeen N; Taylor PA
Blood; 2003 May; 101(9):3741-8. PubMed ID: 12521997
[TBL] [Abstract][Full Text] [Related]
14. Blockade of the OX40 ligand prolongs corneal allograft survival.
Hattori T; Usui Y; Okunuki Y; Sonoda Y; Usui M; Takada E; Mizuguchi J; Yagita H; Okumura K; Akiba H; Takeuchi M
Eur J Immunol; 2007 Dec; 37(12):3597-604. PubMed ID: 18022861
[TBL] [Abstract][Full Text] [Related]
15. 4-1BB and OX40 stimulation enhance CD8 and CD4 T-cell responses to a DNA prime, poxvirus boost vaccine.
Munks MW; Mourich DV; Mittler RS; Weinberg AD; Hill AB
Immunology; 2004 Aug; 112(4):559-66. PubMed ID: 15270726
[TBL] [Abstract][Full Text] [Related]
16. Rejection of human xenoskins by non-CD4 T-cell populations in mice.
Uchida T; Tomita Y; Zheng QW; Kishihara K; Nomoto K; Yasui H
Transplant Proc; 1996 Apr; 28(2):662. PubMed ID: 8623332
[No Abstract] [Full Text] [Related]
17. Activated T cells express the OX40 ligand: requirements for induction and costimulatory function.
Mendel I; Shevach EM
Immunology; 2006 Feb; 117(2):196-204. PubMed ID: 16423055
[TBL] [Abstract][Full Text] [Related]
18. Requirements for the functional expression of OX40 ligand on human activated CD4+ and CD8+ T cells.
Kondo K; Okuma K; Tanaka R; Zhang LF; Kodama A; Takahashi Y; Yamamoto N; Ansari AA; Tanaka Y
Hum Immunol; 2007 Jul; 68(7):563-71. PubMed ID: 17584577
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of allorecognition and skin graft rejection in CD28 and CD40 ligand double-deficient mice.
Habiro K; Kotani M; Omoto K; Kobayashi S; Tanabe K; Shimmura H; Suzuki K; Hayashi T; Toma H; Abe R
Transplantation; 2003 Sep; 76(5):854-8. PubMed ID: 14501867
[TBL] [Abstract][Full Text] [Related]
20. Characterization of rat OX40 ligand by monoclonal antibody.
Satake Y; Akiba H; Takeda K; Atsuta M; Yagita H; Okumura K
Biochem Biophys Res Commun; 2000 Apr; 270(3):1041-8. PubMed ID: 10772947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
